<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02874040</url>
  </required_header>
  <id_info>
    <org_study_id>IC 2012-03</org_study_id>
    <nct_id>NCT02874040</nct_id>
  </id_info>
  <brief_title>Phase II Evaluating Endoresection of the Tumor Scar or Transpupillary Thermotherapy When Endoresection is Not Feasible After Proton Beam Therapy for the Treatment of Large Uveal Melanomas (Endoresection-Laser)</brief_title>
  <official_title>Phase II Evaluating Endoresection of the Tumor Scar or Transpupillary Thermotherapy When Endoresection is Not Feasible After Proton Beam Therapy for the Treatment of Large Uveal Melanomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Curie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Curie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study the efficacy of endoresection of the tumor scar or, when surgery is not possible,
      transpupillary thermotherapy on the tumor scar to prevent neovascular glaucoma and secondary
      enucleation
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-treatment complication incidence.</measure>
    <time_frame>3 years</time_frame>
    <description>observed complications are : Number of glaucomas, numbrer of retinal detachment and number of secondary enucleations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure of tumor scar thickness</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity and side effects evaluation according to NCI-CTCAE v4.0 scale</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Uveal Melanoma</condition>
  <condition>Melanoma, Uveal</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>endoresection of the tumor scar or, when surgery is not possible, transpupillary thermotherapy on the tumor scar</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endoresection</intervention_name>
    <description>Endoresection of the tumor scar</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laser diode</intervention_name>
    <description>Transpupillary thermotherapy by laser diode on the tumor scar</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>Thermotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Tumor of 7 mm of thickness or more

          -  Patients treated by proton beam therapy

          -  Patients aged at least 18 years

          -  Patients clearly informed of the study, having received the letter of information and
             signed the consent

        Exclusion Criteria:

          -  Massive extrascleral extension posterior to the equator

          -  Patients with metastasis at diagnosis.

          -  Patients with glaucoma before the radiation therapy

          -  Patients with opaque media preventing transpupillary thermotherapy

          -  Patients for whom follow up will be difficult due to geographical, social or
             psychological reasons
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurence Desjardins, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Institut Curie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fran√ßois Doz, MD, PhD</last_name>
    <phone>+ 33 (0)1 44 32 45 50</phone>
    <email>francois.doz@curie.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Souhir Neffati</last_name>
    <phone>+ 33 (1)1 56 24 59 44</phone>
    <email>souhir.neffati@curie.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathalie Cassoux, MD, PhD</last_name>
      <phone>+ 33 (0)1 44 32 42 42</phone>
      <email>nathalie.cassoux@curie.fr</email>
    </contact>
    <contact_backup>
      <last_name>Cyrine Ezzili, Sc. PhD</last_name>
      <phone>+ 33 (0)1 56 24 56 48</phone>
      <email>cyrine.ezzili@curie.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Nathalie Cassoux, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2016</study_first_submitted>
  <study_first_submitted_qc>August 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2016</study_first_posted>
  <last_update_submitted>August 16, 2016</last_update_submitted>
  <last_update_submitted_qc>August 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Uveal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

